Theravance Biopharma, Inc.
TBPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $737,592 | $553,452 | $443,875 | $463,969 |
| - Cash | $174,773 | $281,927 | $110,614 | $37,797 |
| + Debt | $44,595 | $46,457 | $48,156 | $49,820 |
| Enterprise Value | $607,414 | $317,982 | $381,417 | $475,992 |
| Revenue | $19,990 | $26,195 | $15,388 | $18,754 |
| % Growth | -23.7% | 70.2% | -17.9% | – |
| Gross Profit | $11,878 | $15,705 | $3,936 | $18,754 |
| % Margin | 59.4% | 60% | 25.6% | 100% |
| EBITDA | -$1,907 | -$2,316 | -$14,021 | -$7,601 |
| % Margin | -9.5% | -8.8% | -91.1% | -40.5% |
| Net Income | $3,615 | $54,835 | -$13,579 | -$15,527 |
| % Margin | 18.1% | 209.3% | -88.2% | -82.8% |
| EPS Diluted | 0.07 | 1.08 | -0.27 | -0.31 |
| % Growth | -93.5% | 500% | 12.9% | – |
| Operating Cash Flow | -$6,508 | $208,074 | $43,039 | -$902 |
| Capital Expenditures | $0 | -$34 | $0 | -$190 |
| Free Cash Flow | -$6,508 | $208,040 | $43,039 | -$1,092 |